Laboratory Assays in the Clinical Management of Antiretroviral Therapy
Summary
- Current guidelines recommend genotypic resistance testing for all HIV-infected persons at entry into care regardless of whether antiretroviral therapy will be initiated (Management Guidelines)[DHHS ART]
- If antiretroviral therapy is deferred, repeat resistance testing should be considered at the time of treatment initiation, particularly in patients at risk of transmission of drug-resistant virus
- If transmitted resistance to integrase inhibitors is suspected, providers may opt to supplement standard testing with an integrase inhibitor genotypic resistance test
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Resistance Testing